- $34.07bn
- $33.26bn
- $5.65bn
S&P 500 top and bottom performing stocks at about 12:00 p.m. EDT
S&P 500 top and bottom performing stocks at about 12:00 p.m. EDT
Brief: Resmed - Enters Accelerated Share Repurchase Agreement To Repurchase $450 Million Of Common Stock - SEC Filing
S&P 500 top and bottom performing stocks at about 03:30 p.m. EDT
S&P 500 top and bottom performing stocks at about 12:00 p.m. EDT
ResMed shares tumble as weak 2027 sales forecast eclipses quarterly profit beat
ResMed Inc. reports results for the quarter ended June 30 - Earnings Summary
Brief: Resmed Q4 Adjusted EPS USD 2.95 Vs. IBES Estimate USD 2.89
Brief: Cleveland Medical Devices Won Favorable PTAB Outcomes In 5 Of 6 Resmed IPR Challenges
U.S. RESEARCH ROUNDUP-BlackRock, Pennant Group, Weyerhaeuser Co
Deals of the day-Mergers and acquisitions
S&P 500 top and bottom performing stocks at about 03:30 p.m. EDT
Deals of the day-Mergers and acquisitions
Deals of the day-Mergers and acquisitions
ResMed to sell software business MatrixCare for $490 million
S&P 500 top and bottom performing stocks at about 03:30 p.m. EDT
Apnimed's sleep apnea pill meets main goal in late-stage study
ResMed beats quarterly profit estimates, names new CFO
Resmed Q3 revenue rises on product demand